SY-5609

Generic Name: SY-5609

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₆F_₃N_₆OP

CAS Number: 2417302-07-7

Unique Ingredient Identifier: TW6044C3O6

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Inavolisib
Drug: Cetuximab
Drug: Bevacizumab
Drug: Atezolizumab
Drug: SY-5609
Drug: Divarasib
Drug: Tiragolumab
Drug: FOLFOX
Drug: FOLFIRI

First Posted Date: 2021-06-18

Last Posted Date: 2024-12-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04929223

Locations: 🇺🇸
cCare, Encinitas, California, United States
🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

and more 78 locations

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Pancreatic Cancer
Advanced Solid Tumor
Small-cell Lung Cancer

Interventions: Drug: SY-5609
Drug: Fulvestrant
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2020-01-29

Last Posted Date: 2023-10-27

Lead Sponsor: Syros Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT04247126

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States

and more 13 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy